Abstract
Proteasomes cut proteins to peptides. The fragments generated by constitutive proteasomes mainly serve for the de novo synthesis of proteins, whereas most peptides produced by immunoproteasomes are antigens. These pivotal functions qualify proteasomes as drug targets. Kyprolis®, a derivative of the natural product epoxomicin, blocks all proteasome types and is approved to treat multiple myeloma. By contrast, immunoproteasome-selective compounds represent promising drugs for autoimmune diseases.
| Translated title of the contribution | Drug development: Proteasome inhibitors - From the basic research in the hospital |
|---|---|
| Original language | German |
| Pages (from-to) | 730-732 |
| Number of pages | 3 |
| Journal | BioSpektrum |
| Volume | 19 |
| Issue number | 7 |
| DOIs | |
| State | Published - Nov 2013 |